These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Supernus Pharmaceuticals will acquire Sage Therapeutics for $12.00 per share in cash, totaling approximately $795 million, including $8.50 per share in cash and a contingent value right worth up to $3.50 per share; Supernus aims to diversify its portfolio by adding Sage's CNS treatment, Zurzuvae. Following the announcement, Sage shares saw a slight increase, and analysts adjusted their price targets, with Canaccord Genuity and Truist Securities raising their targets while Piper Sandler downgraded the stock.

Analysis

Supernus Pharmaceuticals, Inc. (SUPN) has entered into an agreement to acquire Sage Therapeutics, Inc. (SAGE) for a total potential consideration of $12.00 per share, or approximately $795 million. The deal structure comprises $8.50 per share in cash (totaling $561 million) and one non-tradable contingent value right (CVR) worth up to an additional $3.50 per share (up to $234 million). Supernus CEO Jack Khattar articulated that this acquisition is a significant strategic move to bolster future growth by adding Zurzuvae, a CNS treatment, as a fourth key product and further diversifying revenue sources. Following the announcement, Sage Therapeutics shares saw a modest gain of 0.4%, trading at $9.11. Analyst reactions to the deal for Sage were varied: Canaccord Genuity maintained a Hold rating while raising its price target from $8.00 to $8.50, and Truist Securities also maintained a Hold, increasing its price target from $8.00 to $9.00. In contrast, Piper Sandler downgraded Sage Therapeutics from Overweight to Neutral and lowered its price target from $9.00 to $8.50. These analyst price targets predominantly align with or slightly exceed the cash component of the acquisition offer, suggesting a degree of caution or conservatism regarding the full realization of the CVR's value. The current trading price of SAGE above the $8.50 cash floor indicates the market is pricing in some, but not all, of the potential CVR payout.

Key Decisions for Investors

• Sage Therapeutics shareholders should assess the $12.00 per share total offer, recognizing that the $8.50 cash portion is largely supported by current analyst price targets, while the stock's $9.11 trading price implies partial market valuation of the contingent value right.
• Investors must carefully evaluate the probability and potential timeline for the CVR to achieve its maximum $3.50 per share payout, as this component introduces uncertainty not fully captured by the current analyst consensus.
• Considering Sage's stock price is above the guaranteed cash offer and analyst target range, investors might weigh the option of realizing existing gains against holding for the full, but uncertain, CVR payout, especially in light of the mixed analyst ratings post-acquisition announcement.